Browsing Tag
Christoph Antz
3 posts
VERAXA has a $27.5m note and $50m funding facility. Why is Raju Willener becoming CFO now?
VERAXA Biotech has appointed capital-markets veteran Raju Willener as chief financial officer less than three months after its Nasdaq debut, with oncology programmes moving toward clinical development and financing strategy becoming increasingly important.
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.
VERAXA Biotech seals $1.64bn SPAC merger to launch Nasdaq oncology powerhouse
Find out how VERAXA Biotech’s $1.64B Nasdaq listing is set to redefine cancer treatment with next-gen antibody therapies.